Literature DB >> 11302925

Cyp3A regulation: from pharmacology to nuclear receptors.

L C Quattrochi1, P S Guzelian.   

Abstract

Among the human liver cytochrome P450s (P450s), a family of microsomal hemoproteins responsible for catalyzing the oxidative metabolism of clinically used drugs and environmental chemicals, attention has been focused on CYP3A, a form that is the most abundant and is inducible by many of its substrates. From early pharmacological studies that demonstrated induction of CYP3A by glucocorticoids and, paradoxically, by antiglucocorticoids, the existence of a nonclassical glucocorticoid receptor mechanism was inferred and prompted research that culminated in the identification of a unique member of the nuclear receptor family, the pregnane X receptor (PXR; NR1I2). It has become increasingly evident that PXR as well as other nuclear receptors mediate CYP3A induction in a unique and complex manner including inducibility by structurally diverse compounds and striking interspecies differences in induction profiles. Future understanding of the role of nuclear receptors in regulating expression of CYP3A and other genes of the P450 family offers an exciting promise of further defining the physiologic function and interindividual differences of CYP3A in health and disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302925

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

Authors:  Jasper Dingemanse; Dieter Schaarschmidt; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Nuclear receptor PXR: discovery of a pharmaceutical anti-target.

Authors:  Steven A Kliewer
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

Review 3.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

Review 4.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 5.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Authors:  Bodine P S Belderbos; Koen G A M Hussaarts; Leonie J van Harten; Esther Oomen-de Hoop; Peter de Bruijn; Paul Hamberg; Robbert J van Alphen; Brigitte C M Haberkorn; Martijn P Lolkema; Ronald de Wit; Robert J van Soest; Ron H J Mathijssen
Journal:  Br J Clin Pharmacol       Date:  2019-03-21       Impact factor: 4.335

7.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  Adverse effects of vitamin E by induction of drug metabolism.

Authors:  Regina Brigelius-Flohé
Journal:  Genes Nutr       Date:  2007-10-16       Impact factor: 5.523

9.  Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia.

Authors:  Caroline Fradette; Patrick du Souich
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

Review 10.  CAR and PXR: the xenobiotic-sensing receptors.

Authors:  Yoav E Timsit; Masahiko Negishi
Journal:  Steroids       Date:  2006-12-20       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.